Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM study of abiraterone exposure and early biomarkers in metastatic castration-resistant prostate cancer
NL-OMON44680Phase 2Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Ziekenhuisapotheek. Primary endpoint: Primary endpoint: relationship between early abiraterone exposure and treatment response. Started Jul 2015; status: active, not recruiting.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON44680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44680.